Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Protocol ID
APAL2020D
Disease (Sub Disease)
Acute myeloid leukemia
Diagnosis Stage
Relapsed/refractory
Location
QLD, VIC, WA, NZ
Sponsor
LLS PedAL Initiative, LLC
Collaborators
Princess Maxima Center for Pediatric Oncology (European Sponsor)
AbbVie
Roche-Genentech
EuPAL
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Starship Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
29 Days to 21 Years
International registry ID's
NCT05183035
Back to Registry
Study Title A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Protocol ID APAL2020D
Disease (Sub Disease) Acute myeloid leukemia
Diagnosis Stage Relapsed/refractory
Location QLD / VIC / WA / NZ
Sponsor LLS PedAL Initiative, LLC
Collaborators Princess Maxima Center for Pediatric Oncology (European Sponsor)/ AbbVie/ Roche-Genentech/ EuPAL
Links https://clinicaltrials.gov/ct2/show/NCT05183035
Trial Status Open
Trial Open Date 01/10/2022
Sites Perth Children's Hospital/ Queensland Children's Hospital / Starship Hospital / Royal Children's Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility 29 Days to 21 Years
International registry ID's NCT05183035